Bullous Systemic Lupus Erythematosus

Dermatologic Clinics

Volumn 29, Issue 4, 2011, Pages 649-653

  Sebaratnam, Deshan F ^a   Murrell, Dédée F ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Systemic lupus erythematosus; Type VII collagen; Vesiculobullous skin disease

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COLLAGEN TYPE 7; CORTICOSTEROID; DAPSONE; IMMUNOMODULATING AGENT; METHOTREXATE; PREDNISONE; RITUXIMAB;

BULLOUS SKIN DISEASE; BULLOUS SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL FEATURE; DIRECT IMMUNOFLUORESCENCE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; LOW DRUG DOSE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; AUTOANTIBODIES; COLLAGEN TYPE VII; DAPSONE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SKIN DISEASES, VESICULOBULLOUS;

EID: 80052886053     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.06.002     Document Type: Review

References (35)

1. Gammon W.R., Briggaman R.A. Bullous eruption of systemic lupus erythematosus. Management of blistering diseases 1990, 263-275. Chapman and Hall Ltd, London. F. Wojnarowska, R.A. Briggaman (Eds.).
2. Yell J.A., Allen J., Wojnarowska G., et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dematol 1995, 132(6):921-928.
3. Thomas J.R., Daniel Su W.P. Concurrence of lupus erythematosus and dermatitis herpetiformis. A report of nine cases. Arch Dermatol 1974, 119(9):740-745.
4. Bittencourt A.L., Brito E., Sadigursky M., et al. Acta Medica Portuguesa 1984, 5(4-5):119-125. [in Portuguese].
5. Chorzelski T., Jablonska S., Blaszczyk M. Immunopathological investigation in the Senear-Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol 1968, 80(4):211-217.
6. Malik M., Gurcan H.M., Ahmed A.R. Coexistence of mucous membrane pemphigoid and connective-tissue disease. Clin Exp Dermatol 2010, 35(2):156-159.
7. Stoll D.M., King L.E. Association of bullous pemphigoid with systemic lupus erythematosus. Arch Dermatol 1984, 120(3):362-366.
8. Dotson A.D., Raimer S.S., Pursley T.V., et al. Systemic lupus erythematosus occurring in a patient with epidermolysis bullosa acquisita. Arch Dermatol 1981, 117(7):422-426.
9. Alba D., Alvarex-Doforno R., Casado M. Medicina Clinica 1995, 105(2):77-78. [in Spanish].
10. Lau M., Kaufmann-Grunzinger I., Raghunanth M. A case report of a patient with features of systemic lupus erythematosus and linear IgA disease. Br J Dermatol 1991, 124(5):498-502.
11. Morris N.P., Keene D.R., Glanville R.W., et al. The tissue form of type VII collagen is an antiparallel dimer. J Biol Chem 1997, 261(12):5638-5644.
12. Gammon W.R., Murrell D.F., Jenison M.W., et al. Autoantibodies to type VII collagen recognise epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol 1993, 100(5):618-622.
13. Chen M., Marinkovich P., Veis A. Interactions of the amino-terminal non-collagenous (NC1) domain of type VII collagen with extracellular matrix proteins. J Biol Chem 1997, 272(23):14516-14522.
14. Gammon W.R. Autoimmunity to collagen VII: autoantibody-mediated pathomechanisms regulate clinico-pathological phenotypes of acquired epidermolysis bullosa and bullous SLE. J Cutan Path 1993, 20(2):109-114.
15. Chen M., Keene D.R., Costa F.K., et al. The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis bullosa acquisita autoantibodies. J Biol Chem 2001, 276(24):21649-21655.
16. Gammon W.R., Briggaman R.A., Bullouse S.L. A phenotypically distinctive but immunologically heterogenous bullous disorder. J Invest Dermatol 1993, 100(1):28S-34S.
17. Gammon W.R., Briggaman R.A., Inman A.O., et al. Evidence supporting a role for immune complex-mediated inflammation in the pathogenesis of bullous lesions of systemic lupus erythematosus. J Invest Dermatol 1983, 81(4):320-325.
18. Chan L.S., Lapiere J.C., Chen M., et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6 and type VII collagen. Arch Dermatol 1999, 135(5):569-573.
19. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
20. Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol 2004, 22(2):129-138.
21. Hall R.P., Lawley T.J., Smith H.R., et al. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982, 97(2):165-170.
22. Burrows N.P., Bhogal B.S., Black M.M., et al. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br J Dermatol 1993, 128(3):332-338.
23. Fleming M.G., Bergfield M.F., Tomecki K.J. Bullous systemic lupus erythematosus. Int J Dermatol 1989, 28(5):321-326.
24. Yell A.J., Wojnarowska F. Bullous skin disease in lupus erythematosus. Lupus 1997, 6(2):112-121.
25. Barton D.D., Fine J.D., Gammon W.R., et al. Bullous systemic lupus erythematosus: an unusual clinical course and detectable circulating autoantibodies to the epidermolysis bullosa antigen. J Am Acad Dermatol 1986, 15(2):369-373.
26. Gammon W.R., Woodley D.T., Dole K.C., et al. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognise epidermolysis bullosa acquisita autoantigen. J Invest Dermatol 1985, 84(6):472-476.
27. Tatnall F.M., Whitehead P.C., Black M.M., et al. Identification of the epidermolysis bullosa acquisita antigen by LH7.2 monoclonal antibody: use in diagnosis. Br J Dermatol 1989, 120(4):533-539.
28. Jones D.A., Hunt S.W., Prisayanh P.S., et al. Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain. J Invest Dermatol 1995, 104(2):231-235.
29. Camisa C., Sharma H.M. Vesiculobullous systemic lupus erythematosus. J Am Acad Dermatol 1983, 9(6):924-933.
30. Camisa C., Grimwood R.E. Indirect immunofluorescence in vesciculobullous eruption of systemic lupus erythematosus. J Invest Dermatol 1986, 86(5):606.
31. Zhu Y.I., Stiller M.J. Dapsonse and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001, 45(3):420-434.
32. Yung A., Oakley A. Bullous systemic lupus erythematosus. Aust J Dermatol 2000, 41(4):234-237.
33. Fernandez-Sanchez A., Charli-Joseph Y., Saeb-Lima M., et al. Are corticosteroids and immunosuppressors an efficacious treatment for bullous lupus erythematosus with systemic manifestations?. Eur J Dermatol 2010, 20(6):823-824.
34. Malcangi G., Brandozzi G., Giangiacomi M., et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003, 12(1):63-66.
35. Alsanafi S., Kovarik C., Mermelstein A. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheum 2011, 17(3):142-144.